The CAPTAIN trial compared the MRI-Guided TULSA Procedure™ to robotic radical prostatectomy for localized prostate cancer.
Thomas W. Flaig, MD, discusses the 2026 NCCN Guidelines updates for bladder cancer, highlighting the role of enfortumab vedotin, pembrolizumab, and the shift toward neoadjuvant ADC therapy.
Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results